Latest Period
Q2 2026
Security Snapshot
DR REDDYS LABORATORIES LTD - American depositary shares, each representing one equity share (RDY) Institutional Ownership
CUSIP: 256135203
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
237
Shares (Excl. Options)
125,568,007
Price
$14.49
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / American depositary shares, each representing one equity share
- Symbol
- RDY on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 125,568,007
- Total 13F value
- $1,819,048,362
- Portfolio coverage rank
- 0%
- Share change
- +5,658,237
- Value change
- +$82,358,812
- Number of holders
- 237
- Shares outstanding
- 834,731,296
- SEC-reported price per share
- $12.92
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RDY - DR REDDYS LABORATORIES LTD - American depositary shares, each representing one equity share is tracked under CUSIP 256135203.
- 237 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 248 to 237 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,666,506,383 to $1,819,048,362.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 237 institutions filings for Q2 2026.
Security key
256135203
Latest holder period
Q2 2026
13F holders
237
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
RDY full holder history
DR REDDYS LABORATORIES LTD SEC filings
DR REDDYS LABORATORIES LTD company facts
DR REDDYS LABORATORIES LTD insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 256135203:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
RDY
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Prasad G V | 14% | $1,607,395,312 | 113,356,510 | K. Satish Reddy | 17 Sep 2025 |
As of 30 Jun 2026, 237 institutional investors reported holding 125,568,007 shares of DR REDDYS LABORATORIES LTD - American depositary shares, each representing one equity share (RDY). This represents 15% of the company’s total 834,731,296 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
13%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Robeco Institutional Asset Management B.V. | 2.2% | 18,021,100 | +4.9% | 0.32% | $261,125,741 |
| MORGAN STANLEY | 1.3% | 10,936,320 | +17% | 0.01% | $158,467,303 |
| BlackRock, Inc. | 1.3% | 10,585,742 | -8.6% | 0% | $153,387,403 |
| ROYAL BANK OF CANADA | 1.1% | 9,213,268 | -7.7% | 0.02% | $133,514,000 |
| Aikya Investment Management Ltd | 1% | 8,493,852 | +6.2% | 36% | $123,075,915 |
| RENAISSANCE TECHNOLOGIES LLC | 0.88% | 7,347,028 | -6.5% | 0.15% | $106,458,436 |
| DIMENSIONAL FUND ADVISORS LP | 0.64% | 5,312,065 | -0.21% | 0.01% | $77,039,534 |
| STATE STREET CORP | 0.49% | 4,124,686 | +2.4% | 0% | $59,766,700 |
| JPMORGAN CHASE & CO | 0.49% | 4,069,357 | -6.9% | 0% | $60,470,644 |
| ALLIANCEBERNSTEIN L.P. | 0.45% | 3,730,713 | +47% | 0.02% | $51,670,375 |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.37% | 3,100,911 | 0% | 0% | $44,932,200 |
| FRANKLIN RESOURCES INC | 0.34% | 2,844,583 | -0.4% | 0.01% | $41,218,010 |
| Nuveen, LLC | 0.34% | 2,827,699 | 0.01% | $40,973,353 | |
| BNP PARIBAS FINANCIAL MARKETS | 0.32% | 2,649,866 | 0% | 0.02% | $38,396,558 |
| ACADIAN ASSET MANAGEMENT LLC | 0.27% | 2,260,243 | -6.2% | 0.04% | $32,744,000 |
| MARSHALL WACE, LLP | 0.24% | 2,025,356 | -24% | 0.02% | $29,347,409 |
| BESSEMER GROUP INC | 0.22% | 1,857,221 | +1.9% | 0.04% | $26,911,000 |
| AMERICAN CENTURY COMPANIES INC | 0.22% | 1,830,883 | +10% | 0.01% | $26,529,495 |
| UBS Group AG | 0.2% | 1,658,536 | +6.8% | 0% | $24,032,186 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.19% | 1,618,404 | +793% | 0.02% | $24,049,483 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.18% | 1,522,361 | -14% | 0% | $22,059,011 |
| Creative Planning | 0.15% | 1,240,848 | +6.3% | 0.01% | $17,979,881 |
| LAZARD ASSET MANAGEMENT LLC | 0.15% | 1,231,678 | +16% | 0.03% | $17,847,014 |
| GOLDMAN SACHS GROUP INC | 0.13% | 1,053,487 | +75% | 0% | $15,265,022 |
| NORTHERN TRUST CORP | 0.12% | 1,034,651 | -5% | 0% | $14,992,092 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 125,568,007 | $1,819,048,362 | +$82,358,812 | $14.49 | 237 |
| 2026 Q1 | 120,435,423 | $1,666,506,383 | +$206,224,307 | $13.85 | 248 |
| 2025 Q4 | 106,571,030 | $1,496,216,551 | -$7,926,548 | $14.04 | 235 |
| 2025 Q3 | 107,044,315 | $1,496,471,323 | -$18,825,882 | $13.98 | 227 |
| 2025 Q2 | 107,490,178 | $1,615,554,376 | -$2,437,828 | $15.03 | 239 |
| 2025 Q1 | 109,568,130 | $1,445,145,982 | -$147,804,573 | $13.19 | 239 |
| 2024 Q4 | 118,585,675 | $1,871,315,562 | +$1,379,421,949 | $15.79 | 246 |
| 2024 Q3 | 22,323,793 | $1,773,509,164 | -$32,845,620 | $79.45 | 219 |
| 2024 Q2 | 24,129,104 | $1,838,811,719 | +$25,813,649 | $76.19 | 221 |
| 2024 Q1 | 23,624,631 | $1,732,414,047 | +$4,316,081 | $73.35 | 230 |
| 2023 Q4 | 23,549,346 | $1,638,068,047 | -$19,538,179 | $69.58 | 223 |
| 2023 Q3 | 22,552,672 | $1,508,022,257 | +$123,782,702 | $66.87 | 212 |
| 2023 Q2 | 20,723,050 | $1,307,742,762 | +$121,928,914 | $63.11 | 191 |
| 2023 Q1 | 18,804,291 | $1,070,382,001 | +$136,751,438 | $56.93 | 187 |
| 2022 Q4 | 16,423,176 | $849,847,851 | +$3,224,170 | $51.75 | 160 |
| 2022 Q3 | 16,349,824 | $856,712,431 | +$35,896,390 | $52.34 | 147 |
| 2022 Q2 | 15,653,996 | $866,231,781 | -$30,425,047 | $55.39 | 148 |
| 2022 Q1 | 16,608,544 | $923,504,810 | +$4,920,142 | $55.73 | 144 |
| 2021 Q4 | 16,496,810 | $1,073,027,505 | -$47,497,883 | $65.41 | 141 |
| 2021 Q3 | 16,964,108 | $1,105,536,697 | -$93,370,525 | $65.14 | 142 |
| 2021 Q2 | 18,379,985 | $1,350,931,522 | +$10,457,878 | $73.51 | 156 |
| 2021 Q1 | 18,276,597 | $1,128,117,710 | -$17,322,858 | $61.39 | 159 |
| 2020 Q4 | 19,125,629 | $1,364,282,518 | -$153,956,523 | $71.29 | 170 |
| 2020 Q3 | 21,329,258 | $1,481,500,793 | -$17,904,382 | $69.56 | 183 |
| 2020 Q2 | 21,616,772 | $1,145,533,854 | +$16,564,346 | $53.01 | 167 |